mTORC2 Promotes Lipid Storage and Suppresses Thermogenesis in Brown Adipose Tissue in Part Through AKT-Independent Regulation of FoxO1: A Dissertation
Faculty AdvisorDavid A. Guertin, Ph.D.
Academic ProgramInterdisciplinary Graduate Program
UMass Chan AffiliationsProgram in Molecular Medicine
Document TypeDoctoral Dissertation
Adipose Tissue, Brown
TOR Serine-Threonine Kinases
Forkhead Box Protein O1
Brown Adipose Tissue
TOR Serine-Threonine Kinases
Forkhead Box Protein O1
Cellular and Molecular Physiology
MetadataShow full item record
AbstractRecent studies suggest adipose tissue plays a critical role in regulating whole body energy homeostasis in both animals and humans. In particular, activating brown adipose tissue (BAT) activity is now appreciated as a potential therapeutic strategy against obesity and metabolic disease. However, the signaling circuits that coordinate nutrient uptake and BAT function are poorly understood. Here, I investigated the role of the nutrient-sensing mTOR signaling pathway in BAT by conditionally deleting Rictor, which encodes an essential component of mTOR Complex 2 (mTORC2) either in brown adipocyte precursors or mature brown adipocytes. In general, inhibiting BAT mTORC2 reduces glucose uptake and de novo lipogenesis pathways while increases lipid uptake and oxidation pathways indicating a switch in fuel utilization. Moreover, several key thermogenic factors (Ucp1, Pgc1α, and Irf4) are elevated in Rictor-deficient BAT, resulting in enhanced thermogenesis. Accordingly, mice with mTORC2 loss in BAT are protected from HFD-induced obesity and metabolic disease at thermoneutrality. In vitro culture experiments further suggest that mTORC2 cell-autonomously regulates the BAT thermogenic program, especially Ucp1 expression, which depends on FoxO1 activity. Mechanistically, mTORC2 appears to inhibit FoxO1 by facilitating its lysine-acetylation but not through the canonical AKT-mediated phosphorylation pathway. Finally, I also provide evidence that β-adrenergic signaling which normally triggers thermogenesis also induces FoxO1 deacetylation in BAT. Based on these data, I propose a model in which mTORC2 functions in BAT as a critical signaling hub for coordinating nutrient uptake, fuel utilization, and thermogenic gene expression. These data provide a foundation for future studies into the mTORC2-FoxO1 signaling axis in different metabolic tissues and physiological conditions.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/32218
RightsCopyright is held by the author, with all rights reserved.
Showing items related by title, author, creator and subject.
Care Transformation Collaborative Rhode Island: Transforming Primary Care in Rhode IslandCampbell, Susanne; Dell, Sarah; Mobilio, Michael; Brown, Michele; Brown, Candice (2016-09-27)This annual report outlines the 2015 accomplishments of Care Transformation Collaborative (CTC) Rhode Island, a primary care initiative managed by UMass Medical School. CTC includes more than 80 primary care practices across the state. In 2015 CTC had many achievements, including: Improving the cost of care and efficiency – through new programs like our Advanced Collaborative, practices developed and implemented projects focused on improving quality and reducing costs of care. Evaluating, refining and scaling our Community Health Teams – we evaluated the progress of these pilot programs and look forward to building off their successes and lessons learned. Expanding to include additional practices – we have proudly expanded our Collaborative to include pediatric practices, with an increased focus on the needs of children and families. Integrating behavioral health care – we took big steps forward to improve access to behavioral health services within primary care. Expanding our learning curriculum – through ongoing best practice sharing, learning sessions and workshops, we continue to advance our Collaborative through shared learning, leadership development, collaboration, and growth. Improving data analytic capability – we began working toward transitioning to an all-payer claims database to evaluate our practices and programs, increasing actionable reports to practices to support continued progress. The Office of Program Development within UMass Medical School’s Commonwealth Medicine division has been providing project management support for the initiative since 2011 under a contract with The Rhode Island Foundation. UMass Medical School’s Office for Program Development staff assists the Rhode Island primary care initiative by providing leadership, project management, program development and subcontract management support.
Risk Factors Associated with Post-Acute Sequelae of SARS-CoV-2 in an EHR Cohort: A National COVID Cohort Collaborative (N3C) Analysis as part of the NIH RECOVER program [preprint]Hill, Elaine; Mehta, Hemal; Sharma, Suchetha; Mane, Klint; Xie, Catherine; Cathey, Emily; Loomba, Johanna; Russell, Seth; Spratt, Heidi; DeWitt, Peter E; et al. (2022-08-17)Background: More than one-third of individuals experience post-acute sequelae of SARS-CoV-2 infection (PASC, which includes long-COVID). Objective: To identify risk factors associated with PASC/long-COVID. Design: Retrospective case-control study. Setting: 31 health systems in the United States from the National COVID Cohort Collaborative (N3C). Patients: 8,325 individuals with PASC (defined by the presence of the International Classification of Diseases, version 10 code U09.9 or a long-COVID clinic visit) matched to 41,625 controls within the same health system. Measurements: Risk factors included demographics, comorbidities, and treatment and acute characteristics related to COVID-19. Multivariable logistic regression, random forest, and XGBoost were used to determine the associations between risk factors and PASC. Results: Among 8,325 individuals with PASC, the majority were >50 years of age (56.6%), female (62.8%), and non-Hispanic White (68.6%). In logistic regression, middle-age categories (40 to 69 years; OR ranging from 2.32 to 2.58), female sex (OR 1.4, 95% CI 1.33-1.48), hospitalization associated with COVID-19 (OR 3.8, 95% CI 3.05-4.73), long (8-30 days, OR 1.69, 95% CI 1.31-2.17) or extended hospital stay (30+ days, OR 3.38, 95% CI 2.45-4.67), receipt of mechanical ventilation (OR 1.44, 95% CI 1.18-1.74), and several comorbidities including depression (OR 1.50, 95% CI 1.40-1.60), chronic lung disease (OR 1.63, 95% CI 1.53-1.74), and obesity (OR 1.23, 95% CI 1.16-1.3) were associated with increased likelihood of PASC diagnosis or care at a long-COVID clinic. Characteristics associated with a lower likelihood of PASC diagnosis or care at a long-COVID clinic included younger age (18 to 29 years), male sex, non-Hispanic Black race, and comorbidities such as substance abuse, cardiomyopathy, psychosis, and dementia. More doctors per capita in the county of residence was associated with an increased likelihood of PASC diagnosis or care at a long-COVID clinic. Our findings were consistent in sensitivity analyses using a variety of analytic techniques and approaches to select controls. Conclusions: This national study identified important risk factors for PASC such as middle age, severe COVID-19 disease, and specific comorbidities. Further clinical and epidemiological research is needed to better understand underlying mechanisms and the potential role of vaccines and therapeutics in altering PASC course.
Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System [preprint]Moazami, Michael P.; Rembetsy-Brown, Julia M.; Wang, Feng; Krishnamurthy, Pranathi Meda; Weiss, Alexandra; Marosfoi, Miklos G.; King, Robert M.; Motwani, Mona; Gray-Edwards, Heather L.; Fitzgerald, Katherine A.; et al. (2021-02-15)Antisense oligonucleotides (ASOs) are emerging as a promising class of therapeutics for neurological diseases. When injected directly into the cerebrospinal fluid, ASOs distribute broadly across brain regions and exert long-lasting therapeutic effects. However, many phosphorothioate (PS)-modified gapmer ASOs show transient motor phenotypes when injected into the cerebrospinal fluid, ranging from reduced motor activity to ataxia or acute seizure-like phenotypes. The effect of sugar and phosphate modifications on these phenotypes has not previously been systematically studied. Using a behavioral scoring assay customized to reflect the timing and nature of these effects, we show that both sugar and phosphate modifications influence acute motor phenotypes. Among sugar analogues, PS-DNA induces the strongest motor phenotype while 2’-substituted RNA modifications improve the tolerability of PS-ASOs. This helps explain why gapmer ASOs have been more challenging to develop clinically relative to steric blocker ASOs, which have a reduced tendency to induce these effects. Reducing the PS content of gapmer ASOs, which contain a stretch of PS-DNA, improves their toxicity profile, but in some cases also reduces their efficacy or duration of effect. Reducing PS content improved the acute tolerability of ASOs in both mice and sheep. We show that this acute toxicity is not mediated by the major nucleic acid sensing innate immune pathways. Formulating ASOs with calcium ions before injecting into the CNS further improved their tolerability, but through a mechanism at least partially distinct from the reduction of PS content. Overall, our work identifies and quantifies an understudied aspect of oligonucleotide toxicology in the CNS, explores its mechanism, and presents platform-level medicinal chemistry approaches that improve tolerability of this class of compounds.